All News

In honor of Lung Cancer Awareness Month, CURE spoke with Dr. Daniel J. Boffa about how the understanding of lung cancer is evolving beyond smoking.

FOG-001 received fast track designation after early study results showed tumor shrinkage in all evaluable patients with desmoid tumors.

Following the 2025 ESMO Congress, Dr. Joshua Saba sat down with Dr. Chandler Park to discuss recent advances in prostate cancer care.

A woman shares how vision loss led to her cancer diagnosis and how lifestyle changes, support and community helped her regain control after her cancer had spread.

Cindy and Katie share how caring for parents with cholangiocarcinoma led to friendship, support and advocacy through the Cholangiocarcinoma Foundation.

The FDA approved Poherdy as the first interchangeable biosimilar to Perjeta for patients with HER2-positive breast cancer.

As a breast cancer survivor, I try to stay up to date on new ways to detect cancer early. When I first heard about a simple blood test called Cancerguard, I sat up a little straighter.

The FDA has granted orphan drug designation to tinostamustine, an investigational therapeutic, for the treatment of patients with malignant gliomas.

The FDA approved Komzifti in relapsed or refractory acute myeloid leukemia with a susceptible NPM1 mutation.

Leading oncology experts share emerging research and developments shaping the year ahead, from precision medicine to innovative cancer therapies.

After her own breast cancer treatment, Maureen advocated for legislation to make scalp cooling more accessible for patients seeking to preserve their hair.

For Maureen Green, scalp cooling was a crucial part of her breast cancer treatment journey, as it prevented chemotherapy-induced hair loss.

A survivor shares how hearing loss and cancer deepened her grief, leading her to confront denial and embrace support from her church community.

Ten years after first being diagnosed with breast cancer, Cynthia Malaran said she still faces some side effects from treatment, but she has found strategies for coping.

Trial data showed a 62% complete response rate at 6 months with detalimogene coraplasmid among patients with high-risk, BCG-unresponsive bladder cancer.

Tracy Milgram-Posner sat down for an interview with CURE to discuss BRCAStrong and the impact she hopes to make for anyone with breast cancer.

A breast cancer survivor and mother discusses the importance of prioritizing her own needs.

Dr. Joshua Sabari, Dr. Petros Grivas, and Dr. Chandler Park discuss new developments in perioperative therapy for muscle-invasive bladder cancer.

LiveLun invites the Fort Myers lung cancer community to its monthly educational meeting.

Dr. Minetta Liu explains how Signatera detects tumor DNA after bladder surgery, guiding treatment and identifying patients who need immunotherapy.

During my cancer journey, anticipatory anxiety made me ask “what if” questions, but reframing them with hope helped me stay positive and improve my chances of surviving.

Dr. Suneel Kamath sat down for Pancreatic Cancer Awareness Month to discuss advances in treatment and the importance of raising awareness for this disease.

MB-105 received a special FDA status to help deliver faster treatment options for people with relapsed T-cell lymphoma who have few options.

Four-time non-Hodgkin lymphoma survivor Shell Rowe knows very well about the importance of finding the lighthearted side of an otherwise serious situation.

While cancer patients can experience ghosting, and cancer ghosting is real, it is possible to revisit relationships to avoid putting blaming the person who appears to be slipping away.

Dave Nitsche, a nonsmoker and endurance athlete, pushes back against stigma and stays active while advocating for lung cancer screening.

Experts highlight perioperative Padcev plus Keytruda in bladder cancer, showing potential practice-changing results from ESMO 2025 for patients.

I’ve learned that social media can unite people at hereditary cancer risk but often leaves diverse voices out, so real change means every story is seen and valued.